Goldman Sachs
KLRS

Goldman Sachs’s Kalaris Therapeutics KLRS Stock Holding History

Goldman Sachs’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.3K Sell
16,054
-94,449
-85% -$491K ﹤0.01% 6392
2026
Q1 		$638K Buy
110,503
+76,200
+222% +$676K ﹤0.01% 5430
2025
Q4 		$290K Buy
34,303
+11,838
+53% +$75.7K ﹤0.01% 5881
2025
Q3 		$130K Buy
+22,465
New +$74.3K ﹤0.01% 6032
2025
Q1 		– Sell
-518
Closed -$5K – 6485
2024
Q4 		$5K Sell
518
-3,539
-87% -$53.5K ﹤0.01% 5953
2024
Q3 		$75.4K Sell
4,057
-8,464
-68% -$148K ﹤0.01% 5601
2024
Q2 		$208K Buy
12,521
+5,543
+79% +$97.9K ﹤0.01% 5246
2024
Q1 		$121K Sell
6,978
-13,286
-66% -$217K ﹤0.01% 5211
2023
Q4 		$317K Buy
20,264
+6,910
+52% +$272K ﹤0.01% 4973
2023
Q3 		$660K Sell
13,354
-678
-5% -$46.2K ﹤0.01% 4508
2023
Q2 		$1.1M Buy
14,032
+7,009
+100% +$666K ﹤0.01% 4288
2023
Q1 		$636K Sell
7,023
-2,374
-25% -$302K ﹤0.01% 4691
2022
Q4 		$1.11M Buy
9,397
+1,861
+25% +$316K ﹤0.01% 4360
2022
Q3 		$1.37M Sell
7,536
-2,406
-24% -$375K ﹤0.01% 4306
2022
Q2 		$892K Buy
9,942
+5,242
+112% +$550K ﹤0.01% 4702
2022
Q1 		$730K Buy
4,700
+674
+17% +$134K ﹤0.01% 5075
2021
Q4 		$1.2M Sell
4,026
-480
-11% -$223K ﹤0.01% 4687
2021
Q3 		$2.6M Buy
4,506
+1,078
+31% +$499K ﹤0.01% 3948
2021
Q2 		$1.56M Sell
3,428
-8,759
-72% -$4.52M ﹤0.01% 4417
2021
Q1 		$6.56M Buy
12,187
+10,871
+826% +$9.14M ﹤0.01% 2901
2020
Q4 		$1.16M Sell
1,316
-1,397
-51% -$1.07M ﹤0.01% 4098
2020
Q3 		$1.72M Buy
+2,713
New +$1.85M ﹤0.01% 3676

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's KLRS Position: Q2 2026 in Review

Goldman Sachs reduced its Kalaris Therapeutics (KLRS) stake by 85% in Q2 2026, selling an estimated $491K and leaving 16,054 shares worth $65.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6392.

Goldman Sachs first reported a position in KLRS in Q3 2020 and has held it in 22 quarters since. The position peaked at $6.56M in Q1 2021. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Goldman Sachs held 16,054 shares of Kalaris Therapeutics worth $65.3K as of Q2 2026.
  • Goldman Sachs sold 94,449 Kalaris Therapeutics shares in Q2 2026, an estimated $491K.
  • Kalaris Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6392 holding.
  • Goldman Sachs first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Goldman Sachs's Kalaris Therapeutics position peaked at $6.56M in Q1 2021.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.